Response to rates of inhibitor development in previously untreated patients with severe hemophilia a treated with plasma-derived or recombinant factor VIII: No proof of difference or proof of no difference?

摘要

We thank Messori et al for their letter1 regarding our meta-analysis on the role of factor VIII (FVIII) product type in inhibitor development in previously untreated patients (PUPs) with severe hemophilia A, recently published in Seminars in Thrombosis & Hemostasis.2 We highly appreciate their technical reanalysis of our data, which gives us another opportunity to point out some aspects of our research.